Research graph
References from Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 · External reference
Unresolved reference
External reference
Current and future burden of breast cancer: Global statistics for 2020 and 2040
10.1016/j.breast.2022.08.010 · 2022 · External reference
Unresolved reference
External reference
Breast cancer screening practices among Vietnamese women and factors associated with clinical breast examination uptake
10.1371/journal.pone.0269228 · 2022 · External reference
The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases
10.1016/s1470-2045(21)00071-1 · 2021 · External reference
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
10.1126/science.3798106 · 1987 · External reference
Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
10.14196/mjiri.31.88 · 2017 · External reference
10.1200/jop.0718501
10.1200/jop.0718501 · External reference
NICE approves trastuzumab for early stage breast cancer
10.1136/bmj.332.7555.1409-a · 2006 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review
10.1016/j.vhri.2019.02.003 · 2019 · External reference
Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
10.1080/14737167.2020.1819795 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
10.1136/bmj-2021-067975 · 2022 · External reference
Unresolved reference
External reference
11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
10.1016/s0140-6736(16)32616-2 · 2017 · External reference
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study
10.1002/cncr.33154 · 2020 · External reference
Trends in breast cancer incidence in Ho Chi Minh City 1996–2015: A registry-based study
10.1371/journal.pone.0246800 · 2021 · External reference
Female breast cancer in Vietnam: a comparison across Asian specific regions
2015 · External reference
Unresolved reference
External reference
Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model
10.2165/00019053-200725050-00006 · 2007 · External reference
An economic evaluation of adjuvant trastuzumab therapy in HER2‐positive early breast cancer
10.1111/j.1524-4733.2009.00634.x · 2009 · External reference
An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
2013 · External reference
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
10.1016/s0140-6736(07)60028-2 · 2007 · External reference
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
10.1056/nejmoa052122 · 2005 · External reference
Adjuvant trastuzumab in HER2-positive breast cancer
10.1056/nejmoa0910383 · 2011 · External reference
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
10.1200/jco.2014.55.5730 · 2014 · External reference
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
10.1056/nejmoa052306 · 2005 · External reference
The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model
10.1007/s10549-008-0300-2 · 2009 · External reference
Unresolved reference
External reference
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
10.1007/s40273-020-00984-6 · 2021 · External reference
South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states
10.1111/j.1524-4733.2009.00579.x · 2009 · External reference
Health-related quality of life, and its determinants, among older people in rural Vietnam
2010 · External reference
Unresolved reference
External reference
Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force–2
10.1177/0272989x12454941 · 2012 · External reference
Unresolved reference
2011 · External reference
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
10.1186/s12913-019-4715-8 · 2019 · External reference
Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
10.1080/08923973.2022.2090956 · 2022 · External reference
Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy
10.1007/s40273-017-0557-6 · 2018 · External reference
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
10.1016/s1470-2045(13)70225-0 · 2013 · External reference
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
10.1016/s0140-6736(19)30650-6 · 2019 · External reference
